Kinetics of BCR-ABL Transcripts in Imatinib Mesylate treated Chronic Phase CML (CPCML), A Predictor of Response and Progression Free Survival
Journal Title: International Journal of Biomedical Science (IJBS) - Year 2009, Vol 5, Issue 3
Abstract
Purpose: To assess the kinetics of molecular response to Imatinib Mesylate (IM) therapy in predicting progression free survival (PFS), sustained hematological, and cytogenetic responses in CPCML. Methods: Ninety five newly diagnosed CPCML Egyptian patients were treated with IM 400 mg daily dose. Cytogenetic analysis was performed at diagnosis and every 6 months. Molecular monitoring by RT-QPCR was performed at diagnosis and every 3 months during a median follow-up period ( FUp) of 26 months. Mutation detection of ABL domain was performed by ASO-PCR. Results: Hematological response was 98% after three months of IM therapy. Out of 95 patients 59 showed 2 log reduction of BCR-ABL/ABL ratio after 6 months of whom 49 (83%) had complete cytogenetic response (CCyR) and 42 (71%) had major molecular response (MMR) at 12 months. BCR-ABL transcripts remained undetectable in 22 patients (39%) at 26 months. Among the remaining 34 patients not achieving 2 log reduction at 6 months only 5 (15%) had CCyR and MMR by 12 months. ABL domain mutations were detected in 11/15 (73%) resistant and suboptimal responding patients. Achieving 2 log reduction after 6 months of IM therapy significantly correlated with sustained cytogenetic and molecular responses (p<0.0001), with PFS at 2 years (p<0.03) and inversely with ABL gene mutations (p<0.001). Discussion: These data demonstrated the predictive value of early molecular response to IM in CPCML regarding disease course and PFS. A 2 log reduction at 6 months of IM treatment could be a cut off level predicting resistance , CCyR, or suggesting IM dose modification.
Authors and Affiliations
Mahmoud Hossam , Nahas Yasser, Emary Mohamad, Metnawy Wafaa
Keywords
Related Articles
- EP ID EP83275
- DOI -
- Views 112
- Downloads 0
Biomaterials in Maxillofacial Surgery: Membranes and Grafts
Today, significant differences in the use of biomaterials (membranes and grafts) of animal or synthetic origin have yet to be reported. Nevertheless, some evidences suggest that synthetic materials have a lower risk of d...
Use of Gelatinized Maca (Lepidium peruvianum) in Early Postmenopausal Women - a Pilot Study
Objective: This double-blind, placebo-corrected clinical pilot study was aimed at assessing the use of hypocotyls of cruciferous Andean plant Maca (Lepidium peruvianum Chacon), in alleviating symptoms of menopausal disco...
Evaluation of Ginkgo Biloba Extract on Hematological Changes Affected with Hazards of Electromagnetic Field Exposure
The aim of the present work is to study if the GBE 761 (Ginkgo biloba leaves extract) which is beneficial in arterial disease owing to its vasodilator and blood flow acts against the hazards of exposure to electromagneti...
Lower-Dose and Long-Term Intermittent Interferon Therapy for Hepatitis C Genotype 2a may be a Possibility
We report two recent, successful cases in treating active chronic hepatitis C patients (genotype 2a) with a lower-dose and long-term intermittent interferon therapy. Case 1: A 67-year-old female received IFN-alpha 3 MU t...
Free Radicals, Antioxidants in Disease and Health
Free radicals and oxidants play a dual role as both toxic and beneficial compounds, since they can be either harmful or helpful to the body. They are produced either from normal cell metabolisms in situ or from external...